Literature DB >> 28623146

An update of the global burden of pertussis in children younger than 5 years: a modelling study.

Karene Hoi Ting Yeung1, Philippe Duclos2, E Anthony S Nelson1, Raymond Christiaan W Hutubessy3.   

Abstract

BACKGROUND: Since the publication in 2003 of a model to estimate the disease burden of pertussis, new evidence of the protective effect of incomplete pertussis vaccination against severe pertussis has been reported. We revised the model to provide new estimates of regional and global pertussis cases and deaths for children younger than 5 years.
METHODS: We developed a revised model with data from 2014 to estimate pertussis cases and deaths. Pertussis cases were defined according to the WHO clinical case definition, as a coughing illness lasting at least 2 weeks with paroxysms of coughing, inspiratory whooping, or post-tussive vomiting. We used UN population estimates and WHO and UNICEF data on national pertussis immunisation coverage. Estimates were made for vaccine effectiveness against pertussis cases and deaths for one, two, and three doses of vaccination, probability of infection in low and high coverage countries, and case fatality ratios in low and high mortality countries in two age groups: infants younger than 1 year and children aged 1-4 years. We did sensitivity analyses with a range of input parameters to assess the effect of uncertainty of the input parameters on the model outputs.
FINDINGS: We estimated that there were 24·1 million pertussis cases and 160 700 deaths from pertussis in children younger than 5 years in 2014, with the African region contributing the largest proportions (7·8 million [33%] cases and 92 500 [58%] deaths). 5·1 million (21%) estimated pertussis cases and 85 900 (53%) estimated deaths were in infants younger than 1 year. In the sensitivity analyses, the estimated number of cases ranged from 7 million to 40 million and deaths from 38 000 to 670 000.
INTERPRETATION: Our estimates suggest that, compared with the 1999 estimates published in 2003 (30·6 million pertussis cases and 390 000 deaths from pertussis in children younger than 5 years), the numbers of cases and deaths of pertussis have fallen substantially. Model sensitivity emphasised the importance of better surveillance to improve country-level decision making and pertussis control. FUNDING: None.
Copyright © 2017 World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28623146     DOI: 10.1016/S1473-3099(17)30390-0

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  103 in total

1.  Peptidoglycan Recognition Protein 4 Suppresses Early Inflammatory Responses to Bordetella pertussis and Contributes to Sphingosine-1-Phosphate Receptor Agonist-Mediated Disease Attenuation.

Authors:  Ciaran Skerry; William E Goldman; Nicholas H Carbonetti
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

2.  Multicenter Clinical Evaluation of the Automated Aries Bordetella Assay.

Authors:  Ryan F Relich; Amy Leber; Stephen Young; Ted Schutzbank; Ronald Dunn; Janet Farhang; Timothy S Uphoff
Journal:  J Clin Microbiol       Date:  2019-01-30       Impact factor: 5.948

3.  Questionnaire survey on maternal pertussis vaccination for pregnant women and mothers in Nara prefecture, Japan.

Authors:  Taito Kitano; Tomoko Onishi; Masahiro Takeyama; Midori Shima
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

4.  Pertussis vaccination in pregnancy in Canada: a cost-utility analysis.

Authors:  Bahaa Abu-Raya; Doug Coyle; Julie A Bettinger; Wendy Vaudry; Scott A Halperin; Manish Sadarangani
Journal:  CMAJ Open       Date:  2020-10-19

5.  Histopathology of Bordetella pertussis in the Baboon Model.

Authors:  Lindsey I Zimmerman; James F Papin; Jason Warfel; Roman F Wolf; Stanley D Kosanke; Tod J Merkel
Journal:  Infect Immun       Date:  2018-10-25       Impact factor: 3.441

6.  Evaluation of the Aries Bordetella Assay for Detection and Identification of Bordetella pertussis in Nasopharyngeal Swab Specimens.

Authors:  T McMillen; H Y Chow; Shubhagata Das; Sherry A Dunbar; N E Babady
Journal:  J Clin Microbiol       Date:  2019-04-26       Impact factor: 5.948

7.  Long-lived immunity to genetically detoxified pertussis vaccines.

Authors:  Camille Locht
Journal:  EClinicalMedicine       Date:  2021-07-06

8.  Chemical Synthesis and Immunological Evaluation of a Pentasaccharide Bearing Multiple Rare Sugars as a Potential Anti-pertussis Vaccine.

Authors:  Peng Wang; Chang-Xin Huo; Shuyao Lang; Kyle Caution; Setare Tahmasebi Nick; Purnima Dubey; Rajendar Deora; Xuefei Huang
Journal:  Angew Chem Int Ed Engl       Date:  2020-02-25       Impact factor: 15.336

9.  Nucleobase Modified Adefovir (PMEA) Analogues as Potent and Selective Inhibitors of Adenylate Cyclases from Bordetella pertussis and Bacillus anthracis.

Authors:  Michal Česnek; Jan Skácel; Petr Jansa; Martin Dračínský; Markéta Šmídková; Helena Mertlíková-Kaiserová; Monica P Soto-Velasquez; Val J Watts; Zlatko Janeba
Journal:  ChemMedChem       Date:  2018-07-31       Impact factor: 3.466

10.  Knowledge, perception and maternal immunisation practices of obstetricians in Singapore for the Tdap and influenza vaccines.

Authors:  Serene Thain; Shu Qi Tan; Shephali Tagore
Journal:  Singapore Med J       Date:  2019-12-10       Impact factor: 1.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.